

MIGRAINE CALCITONIN GENE-RELATED PEPTIDE (CGRP) ANTAGONISTS NASAL ZAVZPRET (zavegepant)

Pre - PA Allowance

None

Prior-Approval Requirements

Age 18 years of age or older

Diagnosis

Patient must have the following:

1. Acute treatment of migraine with or without aura

AND ALL of the following:

- a. **NOT** used for the prevention of migraines
- b. Patient has completed an adequate 3-month trial **OR** patient has an intolerance or contraindication to at least **TWO** Triptan Agents
- c. **NO** dual therapy with Triptan Agents at Prior Authorization quantities
- d. Patient has **ONE** of the following:
 1. **NO** dual therapy with another CGRP antagonist (see Appendix 1)
 2. Dual therapy with a migraine preventative CGRP antagonist if **ONE** of the following applies:
 - i. Patient has completed an adequate 3-month trial of at least 2 migraine preventative CGRP antagonists (i.e., Aimovig, Ajovy, Emgality, Nurtec ODT, Qulipta, and Vyepti)
 - ii. Patient has completed an adequate 3-month trial of a migraine preventative CGRP antagonist in combination with a triptan agent
- e. Patient **MUST** have tried the preferred product (Nurtec ODT) unless the patient has a valid medical exception (e.g., inadequate treatment response, intolerance, contraindication)

Prior - Approval Limits

Quantity

Medication/Strength	Diagnosis	Quantity
Zavzpret 10 mg	Acute treatment	24 nasal spray devices per 90 days

MIGRAINE CALCITONIN GENE-RELATED PEPTIDE (CGRP) ANTAGONISTS NASAL ZAVZPRET (zavegepant)

Duration 6 months

Prior – Approval *Renewal* Requirements

Age 18 years of age or older

Diagnosis

Patient must have the following:

1. Acute treatment of migraine with or without aura

AND ALL of the following:

- a. **NOT** used for the prevention of migraines
- b. **NO** dual therapy with Triptan Agents at Prior Authorization quantities
- c. Patient has **ONE** of the following:
 1. **NO** dual therapy with another CGRP antagonist (see Appendix 1)
 2. Dual therapy with a migraine preventative CGRP antagonist if **ONE** of the following applies:
 - i. Patient has completed an adequate 3-month trial of at least 2 migraine preventative CGRP antagonists (i.e., Aimovig, Ajovy, Emgality, Nurtec ODT, Qulipta, and Vyepti)
 - ii. Patient has completed an adequate 3-month trial of a migraine preventative CGRP antagonist in combination with a triptan agent
- d. Patient **MUST** have tried the preferred product (Nurtec ODT) unless the patient has a valid medical exception (e.g., inadequate treatment response, intolerance, contraindication)

Prior - Approval *Renewal* Limits

Quantity

Medication/Strength	Diagnosis	Quantity
Zavzpret 10 mg	Acute treatment	24 nasal spray devices per 90 days

Duration 12 months

**MIGRAINE CALCITONIN GENE-RELATED PEPTIDE (CGRP) ANTAGONISTS NASAL
ZAVZPRET (zavegepant)**

Appendix 1 - List of CGRP Antagonists

Generic Name	Brand Name
atogepant	Qulipta
eptinezumab-jjmr	Vyepti
erenumab-aooe	Aimovig
fremanezumab-vfrm	Ajovy
galcanezumab-gnim	Emgality
rimegepant	Nurtec ODT
ubrogepant	Ubrelvy
zavegepant	Zavzpret